Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or a female (not pregnant and agreeable to take birth control measures until one month after study completion)~* Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²)~* Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results~* Are nonsmokers, have not smoked for at least 6 months prior to entering the study~Exclusion Criteria:~* Are currently participating in or completed a clinical trial within the last 30 days~* Have previously participated or withdrawn from this study~* Have donated blood or have blood loss of more than 500 mL within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY900014 (Type: EXPERIMENTAL): Single dose of 7 units (U), 15 U, and 30 U of LY900014 administered subcutaneously (SC) in three of six periods.
- Insulin Lispro (Humalog) (Type: ACTIVE_COMPARATOR): Single dose of 7 U, 15 U, and 30 U of insulin lispro administered SC in three of six periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).